{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T04:02:23Z","timestamp":1746417743258,"version":"3.40.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T00:00:00Z","timestamp":1626998400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, keeps spreading globally. Evidence suggests that a subgroup of patients with severe symptomatology might have cytokine storms, which increases mortality. The use of interleukin-6 (IL-6) inhibitors may help in controlling the pathological immune response to the virus. Tocilizumab, a monoclonal antibody against IL-6, stands as an optional treatment for COVID-19 patients presenting this inflammatory hyper-response.<\/jats:p>\n            <jats:p>We conducted a retrospective, observational, cohort study including 50 patients affected by COVID-19 with severe pneumonia and poor prognosis criteria, who have also undergone standard treatment; 36 of these patients additionally received tocilizumab in an early stage. The need for intensive care unit (ICU) admission, mortality, recovery of respiratory function, and improvement of biochemical and hematological parameters were compared between cohorts.<\/jats:p>\n            <jats:p>Most patients were men, non-smokers and the most frequently reported comorbidities were hypertension and diabetes. Recurrent symptoms were fever, cough, and dyspnoea. 54.8% of patients from the tocilizumab group needed intubation, while in the control group 85.7% needed it. Treatment with tocilizumab significatively increased IL-6 levels, (554.45; CI 95% 186.69, 1032.93; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) while C-reactive protein mean levels were reduced (\u2013108.19; CI 95% \u2013140.15, \u201375.33; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05), but no significant difference was found between cohorts. In comparison with the controls, tocilizumab reduced mortality (25.0% vs 42.9%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.021) and the number of ICU admissions (63.9% vs 100.0%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.021). 44.1% of patients treated with tocilizumab showed favorable radiological evolution, when compared with 15.4% of patients from the control group.<\/jats:p>\n            <jats:p>Tocilizumab may improve clinical symptoms and mitigate deterioration observed in severe COVID-19 patients, and could be considered as an effective therapeutic option in subjects experiencing a significant inflammatory response to the disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026533","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T20:01:54Z","timestamp":1628193714000},"page":"e26533","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria"],"prefix":"10.1097","volume":"100","author":[{"given":"Pedro","family":"S\u00e1nchez-Rovira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"P\u00e9rez-Chica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Laura","family":"Ortega-Granados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefa","family":"Aguilar-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"D\u00edaz-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"G\u00e1lvez-Montosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Garc\u00eda-Verdejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Luque-Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Quero-Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Fern\u00e1ndez-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ruiz-Bail\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Yaguez-Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Francisco","family":"Mar\u00edn-Pozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Isabel","family":"Sierra-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Lac\u00e1rcel-Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaspar Jes\u00fas","family":"Duro-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Duro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garc\u00eda-Alegr\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Herrero-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,7,23]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.7150\/ijbs.45472","article-title":"Zoonotic origins of human coronaviruses","volume":"16","author":"Ye","year":"2020","journal-title":"Int J Biol Sci"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s11684-020-0767-8","article-title":"Coronavirus disease 2019 (COVID-19): a clinical update","volume":"14","author":"Zhou","year":"2020","journal-title":"Front Med"},{"key":"R3-20250504","first-page":"v1","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"202003","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S2665-9913(20)30092-8","article-title":"Preventing COVID-19-induced pneumonia with anticytokine therapy","volume":"2","author":"Monteleone","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"101623","DOI":"10.1016\/j.tmaid.2020.101623","article-title":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis","volume":"34","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"P475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)","volume":"111","author":"Liu","year":"2020","journal-title":"J Autoimmun"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1148\/radiol.2020200280","article-title":"CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia","volume":"295","author":"Fang","year":"2020","journal-title":"Radiology"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"104380","DOI":"10.1016\/j.jcv.2020.104380","article-title":"Supportive treatment with tocilizumab for COVID-19: a systematic review","volume":"127","author":"Alzghari","year":"2020","journal-title":"J Clin Virol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J Med Virol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality","volume":"55","author":"Zhang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/jmv.25897","article-title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection","volume":"92","author":"Di Giambenedetto","year":"2020","journal-title":"J Med Virol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","article-title":"Why tocilizumab could be an effective treatment for severe COVID-19?","volume":"18","author":"Fu","year":"2020","journal-title":"J Transl Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diii.2020.03.010","article-title":"Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab","volume":"101","author":"Cellina","year":"2020","journal-title":"Diagn Interv Imaging"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.annonc.2020.03.300","article-title":"Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report","volume":"31","author":"Michot","year":"2020","journal-title":"Ann Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"104659","DOI":"10.1016\/j.oraloncology.2020.104659","article-title":"New therapeutic opportunities for COVID-19 patients with Tocilizumab: possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws","volume":"106","author":"Bennardo","year":"2020","journal-title":"Oral Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1186\/s13054-020-03429-w","article-title":"Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study","volume":"24","author":"Li","year":"2020","journal-title":"Crit Care"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.medmal.2020.05.001","article-title":"Tocilizumab therapy reduced intensive care unit admissions and\/or mortality in COVID-19 patients","volume":"50","author":"Klopfenstein","year":"2020","journal-title":"Med Mal Infect"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar4397","article-title":"Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis","volume":"15","author":"Isaacs","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:34:52Z","timestamp":1746336892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026533"}},"subtitle":["Impact on mortality rate and intensive care unit admission"],"short-title":[],"issued":{"date-parts":[[2021,7,23]]},"references-count":29,"journal-issue":{"issue":"29","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026533","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,7,23]]},"assertion":[{"value":"2020-12-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}